Research and development cost money and the company has utilized friendly debt from directors to achieve FDA approval/clearance of devices that have the potential to produce over $100M in revenue over the next 5 years. Recent favorable changes in insurance reimbursement should prove to be a boon as device placement (DermaPace) has accelerated. Each device placed can generate $500-$1000/ week in revenue; I expect we will see updates on that progress soon. The company is well positioned for success.
News 
Market Data 
Discover 
